GAL and neoplasm: The TEID can be conveniently prepared by encapsulating SLO‐Gal&SLO‐NEU in HA shell to achieve targeted delivery, HAase‐induced degradation in tumor microenvironment, and easily anchoring of SLO‐Gal and SLO‐NEU on tumor cells to perform the Gal‐introduction, SA‐cleavage and perforation in vivo, which exhibits the significant enhancement of immunotherapeutic efficacy of the tumors through simultaneously boosting NK cell activation, weakening immune cell inhibition and promoting the delivery of NK cell‐secreted cytokines.